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ABSTRACT
The majority of breast cancers express estrogen receptor α (ERα), and most 
patients with ERα-positive breast cancer benefit from antiestrogen therapy. The ERα-
modulator tamoxifen and ERα-downregulator fulvestrant are commonly employed 
antiestrogens. Antiestrogen resistance remains a clinical challenge, with few 
effective treatments available for patients with antiestrogen-resistant breast cancer. 
Hypoxia, which is intrinsic to most tumors, promotes aggressive disease, with the 
hypoxia-inducible transcription factors HIF1 and HIF2 regulating cellular responses 
to hypoxia. Here, we show that the ERα-expressing breast cancer cells MCF-7, 
CAMA-1, and T47D are less sensitive to antiestrogens when hypoxic. Furthermore, 
protein and mRNA levels of HIF2α/HIF2A were increased in a panel of antiestrogen-
resistant cells, and antiestrogen-exposure further increased HIF2α expression. 
Ectopic expression of HIF2α in MCF-7 cells significantly decreased sensitivity to 
antiestrogens, further implicating HIF2α in antiestrogen resistance. EGFR is known 
to contribute to antiestrogen resistance: we further show that HIF2α drives hypoxic 
induction of EGFR and that EGFR induces HIF2α expression. Downregulation or 
inhibition of EGFR led to decreased HIF2α levels. This positive and bilateral HIF2-
EGFR regulatory crosstalk promotes antiestrogen resistance and, where intrinsic 
hypoxic resistance exists, therapy itself may exacerbate the problem. Finally, 
inhibition of HIFs by FM19G11 restores antiestrogen sensitivity in resistant cells. 
Targeting HIF2 may be useful for counteracting antiestrogen resistance in the clinic.
INTRODUCTION
Selective estrogen receptor modulators (SERMs) like 
tamoxifen, and selective estrogen receptor down-regulators 
(SERDs) like fulvestrant, are widely used to treat estrogen 
receptor α (ERα)-positive breast cancer. These drugs 
reduce tumor growth and metastasis by counteracting 
ERα-induced proliferation [1]. Antiestrogen resistance 
frequently occurs, particularly in patients with high-
stage disease [2], posing a prominent clinical difficulty. 
Resistance can be intrinsic (de novo resistance), but more 
commonly it arises during treatment (acquired resistance).
ERα (encoded by ESR1 or NR3A1) binds estrogen 
(the most potent estrogen is estradiol, E2) in a hydrophobic 
pocket, inducing receptor conformational changes, dimer 
formation and transcriptional regulation of genes with ERα 
binding-sites in their promoters. Tamoxifen and its active 
metabolite 4-hydroxytamoxifen, competitively binds to the 
same hydrophobic pocket in ERα as E2 does, but induces 
a different conformational change to modulate, although 
not completely abolish, ERα signaling [3]. SERDs also 
bind to this hydrophobic pocket to induce conformational 
changes that abolish ERα signaling and cause proteasomal 
degradation of ERα [4]. 
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Most solid tumors harbor poorly oxygenated, 
hypoxic, areas due to insufficient circulation. Hypoxia 
results in the stabilization and activation of the hypoxia-
inducible transcription factor alpha-subunits HIF1α and 
HIF2α [5, 6]. To induce transcription, the alpha-subunits 
dimerize with HIFβ/ARNT and translocate to the nucleus, 
where HIFα/HIFβ-complexes bind hypoxia-responsive 
element (HRE) sites in the promoters of genes including 
vascular endothelial growth factor (VEGF) and EPO. 
Stabilization of HIF1α and HIF2α contributes to hypoxic 
cell survival and neovascularization [7]. It is well known 
that tumor hypoxia is associated with poor prognosis 
and therapeutic resistance [8]. Our laboratory previously 
reported that high HIF2α protein levels are associated with 
distant metastases and poor outcomes in breast cancer 
patients [9]. 
Activation of alternative growth and survival 
signaling pathways, e.g. human epidermal growth factor 
receptor (HER1 or EGFR) and HER2, has been described 
in antiestrogen therapy-resistant breast cancer [10, 11]. 
HIF1α and HIF2α are implicated in therapeutic resistance 
in breast cancer [12, 13], and HIF2α influences EGFR 
translation [14, 15] at hypoxia. To test if hypoxia per se 
can induce antiestrogen resistance and to establish the 
mechanisms for the potential hypoxia-induced resistance, 
we investigated how hypoxia and HIFs affect sensitivity 
to tamoxifen and fulvestrant. We observed that hypoxic 
conditions increased the proportion of viable cells after 
antiestrogen treatment. HIF2α expression was increased 
in antiestrogen-resistant cells, and co-treatment with 
the HIF-inhibitor FM19G11 restored their antiestrogen 
sensitivity. Ectopic expression of HIF2α significantly 
increased the viability of MCF-7 cells after exposure 
to tamoxifen or fulvestrant, further strengthening the 
link between HIF2α and antiestrogen resistance. EGFR 
expression was increased in antiestrogen-resistant cells (as 
previously reported for fulvestrant-resistant cells [16]) and 
further induced by hypoxia. Silencing HIF2α significantly 
lowered EGFR expression, whereas HIF2α overexpression 
induced EGFR. Finally, EGFR induced HIF2α expression, 
suggesting that these two proteins form a positive 
regulatory-loop that promotes antiestrogen resistance.
RESULTS
Effects of hypoxia on antiestrogen treatment in 
ERα-positive breast cancer cells
We hypothesized that hypoxia would reduce 
the effect of antiestrogen treatment, since ERα is 
downregulated in response to hypoxia (Figure 1A). 
Tamoxifen treatment resulted in increased protein 
expression of ERα, whereas fulvestrant treatment led 
to decreased protein expression of ERα (Figure 1A), as 
anticipated [4], and the hypoxic ERα-downregulating 
effect persisted in antiestrogen-treated cells (Figure 1A). 
We next examined if antiestrogen sensitivity was 
affected by hypoxia in ERα-positive cell lines: MCF-7, 
CAMA-1, and T47D. All three cell lines were less sensitive 
to antiestrogens under hypoxic conditions (Figure 1B). 
However, the transcriptional activity of ERα was not 
affected by hypoxia as assessed by an ERα luciferase 
reporter assay (Figure 1C), suggesting that ERα itself is 
unlikely to be responsible for the decreased antiestrogen 
effect during hypoxia.
Since HIFs are important mediators of hypoxic 
adaptation, HIF1α and HIF2α protein levels were 
assessed in MCF-7 cells after 72 h (a time-point at which 
neither tamoxifen nor fulvestrant had caused significant 
differences in cell density) in the absence or presence 
of antiestrogen showing similar accumulation of both 
factors under hypoxic conditions (Figure 1D). Dipyridyl 
(DIP) treatment leads to HIFα protein accumulation by 
inhibiting VHL-dependent proteasomal degradation and 
was used as a positive control for HIF1α and HIF2α 
protein detection (Figure 1D). The kinetics of HIF1α and 
HIF2α accumulation in response to hypoxia varied, with 
HIF1α expression increasing prior to 6 h and declining at 
72 h (Figure 1E). In contrast, HIF2α protein expression 
continued to increase even at 72 h of hypoxia (Figure 1E). 
We did not detect significant differences in cell density 
between control and drug-exposed cells as early as at 72 h 
of exposure (data not shown), which may indicate that any 
HIF-dependent influence on sensitivity is likely to be via 
the action of HIF2α as this is the dominating isoform at 
later time-points. 
To further analyze the nature of hypoxia-induced 
antiestrogen resistance, we utilized a panel of antiestrogen-
resistant cell lines that were generated from MCF-7 cells 
surviving longterm treatment with growth arresting 
concentration of tamoxifen (TAMR1) or fulvestrant 
(FUR1 and FUR2) [17–19]. As anticipated, an increased 
percentage of drug-resistant cells survived exposure to 
antiestrogens compared to parental MCF-7 cells (Figure 1F 
and Supplementary Figure S1). Notably, resistance was 
further increased under hypoxic conditions (Figure 1F and 
Supplementary Figure S1).
Breast cancer cells with acquired antiestrogen 
resistance have increased protein levels of 
HIF2α, but not HIF1α
We next investigated HIF protein levels in the 
antiestrogen-resistant cell lines TAMR1, FUR1, and 
FUR2. All three resistant cell lines expressed HIF1α 
protein at levels comparable to, or lower than, the parental 
cell line under normoxic (where HIF1α protein is hardly 
detectable) and hypoxic conditions at 72 h (Figure 2A–2C, 
upper panels). HIF2α was detected under normoxic 
conditions in all three antiestrogen-resistant cell lines, 
with expression further increasing with hypoxia; however, 
in parental MCF-7 cells, HIF2α expression was robust 
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mainly under hypoxic conditions (Figure 2A–2C). HIF2α 
signals were quantified and normalized to SDHA levels 
(Figure 2A–2C, graphs): both tamoxifen- (TAMR1) and 
fulvestrant-resistant (FUR1 and FUR2) cells expressed 
significantly higher levels of HIF2α protein compared 
to parental cells under normoxic and hypoxic conditions 
(Figure 2A–2C). Furthermore, HIF2α protein levels 
increased significantly with drug-exposure in hypoxic 
antiestrogen-resistant cells, a trend also visible at normoxia 
(Figure 2A–2C). ERα levels were lower in TAMR1 cells 
Figure 1: Effects of hypoxia and antiestrogen treatment in estrogen receptor-positive breast cancer cells. (A) Treatment 
of MCF-7 cells with 0.5 µM tamoxifen for 72 h at normoxic and hypoxic conditions results in increased protein levels of ERα. Fulvestrant 
has the opposite effect. Actin was used as a loading control. (B) Cell viability displayed as percentage of untreated control cells (C) for three 
ERα-positive cell lines: MCF-7, CAMA-1, and T47D. The cells were counted after exposure to antiestrogens under hypoxic (1%) or control 
(21%) conditions for six days. Three independent experiments in triplicate were performed for each cell line. The differences in percentages 
of surviving cells were significant where indicated (*). In the other settings (n.s.), the differences were statistically significant in two of 
the three experiments. Student’s t-test, significance *p < 0.05. (C) Transcriptional activity of ERα in MCF-7 cells analyzed by an ERE-
luciferase assay under control (21%) and hypoxic (1%) conditions with and without addition of 17-β-estradiol (E2) for 24 h to the culture 
medium. (D) western blot analyses for HIF1α and HIF2α in MCF-7 cells cultured under the indicated oxygen conditions for 72 h. Dipyridyl 
(DIP) treatment leads to HIF α-subunit accumulation and was used to generate positive controls for western blots since the HIF2α antibody 
also detects a non-specific product. DIP indicates exposure for 24 h [100 μM]; less amount of sample was loaded to avoid overflow into 
adjacent wells. SDHA was used as a loading control. The HIF2α protein is indicated with a line. (E) Western blot for HIF1α and HIF2α at the 
indicated time points of exposure to hypoxic conditions (1% oxygen). SDHA was used as a loading control. The HIF2α protein is indicated 
with a line. (F) Cell viability (% of non-drug-treated control cells) after six days of tamoxifen [0.5 μM] or fulvestrant [0.5 μM] exposure to 
tamoxifen- (TAMR1) and fulvestrant- (FUR1 and 2) resistant MCF-7 cells at 21% oxygen and 1% oxygen, respectively. Data presented are 
the mean from three independent experiments in triplicate. Statistical analysis with Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001.
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than in MCF-7 parental cells, increased with tamoxifen 
treatment, and decreased at hypoxia (Figure 2D). FUR1 
also expressed less ERα than parental MCF-7 cells and, 
at hypoxia and in the presence of fulvestrant, ERα levels 
further decreased and was hardly detectable (Figure 2D). 
FUR2 cells expressed ERα at levels comparable to MCF-7 
cells under control conditions, but in fulvestrant- or 
hypoxia-treated cells ERα levels were consistently lower 
(Figure 2D). Since low protein levels of ERα (hypoxia 
and fulvestrant treatment) and impaired function of ERα 
(tamoxifen) were associated with high protein levels 
of HIF2α, we examined the effect of siRNA-mediated 
knockdown of ERα in these cells. Following reduction of 
ERα increased protein levels of HIF2α were observed two 
days after transfection (Supplementary Figure S2).
Treatment of patients with high doses of estrogen 
has been suggested as a strategy against progressed 
hormone-responsive breast cancer [20, 21]. Incubation 
with high concentrations of 17β-estradiol (10 μM) for 
72 h (i.e. before decreased cell numbers in treated cultures 
are seen at 6–7 days) lead to increased HIF2α protein 
levels in both MCF-7 and antiestrogen-resistant cell lines 
(Supplementary Figure S2). In the resistant cells, but 
not in MCF-7, a slight increase in EGFR levels was also 
seen, which may reflect a stress response, especially in 
the resistant cell lines, since estrogen induces apoptosis 
in breast cancer cells adapted to long-term estrogen 
deprivation [22]. 
HIF2A mRNA levels are elevated in antiestrogen 
resistant cells
It is thought that both HIF1α and HIF2α are 
primarily regulated by protein stabilization in response 
to low oxygen levels; however, we observed that the 
protein levels of HIF2α in the developing sympathetic 
nervous system and in hypoxic neuroblastoma are at least 
partially regulated transcriptionally [23]. Analysis of 
HIF2A (EPAS1) mRNA expression after 72 h of exposure 
to tamoxifen and fulvestrant revealed that HIF2A mRNA 
expression was higher in TAMR1, FUR1, and FUR2 cells 
than in parental MCF-7 cells under normoxic and hypoxic 
conditions (Figure 3A–3C). Interestingly, HIF2A mRNA 
expression was consistently greater in hypoxic cells than 
corresponding normoxic cells (Figure 3D). We conclude 
that increased HIF2α protein expression in breast cancer 
cells appears to be regulated transcriptionally in response 
to hypoxia, at least in part. Analysis of published cDNA 
microarray data [24] revealed 12-fold greater HIF2A 
mRNA expression in four tamoxifen-resistant cell lines 
(including TAMR1) than the parental cell line (p < 0.001), 
and 26-fold greater mRNA expression in seven 
fulvestrant-resistant cell lines including FUR1 and FUR2 
(p < 0.001). In contrast, the HIF1A mRNA levels did not 
vary significantly between the antiestrogen-resistant cells 
and the parental MCF-7 cells or with exposure to drugs 
or hypoxic conditions (data not shown), consistent with a 
post-transcriptional hypoxic induction of HIF1α.
HIF inhibition restores sensitivity to 
antiestrogens in resistant cells
We next sought to inhibit HIF2α activity in 
antiestrogen-resistant cells to test the hypothesis that 
this would restore antiestrogen sensitivity. As shown 
above (Figure 1E), HIF2α appears to play a greater role 
than HIF1α in processes occurring at or after 72 h of 
hypoxia. Since knock-down experiments using siHIF2A 
and shHIF2A were unsuccessful over longer periods of 
antiestrogen exposure (six to nine days), we exploited a 
commercially available and well-tolerated HIF inhibitor, 
FM19G11 [25], which inhibits both HIF1 and HIF2 
activities and decreases expression of downstream target 
genes [25].
To ensure efficacy of the HIF-inhibitor, FM19G11, 
in these cell lines, HRE-luciferase reporter assays were 
performed to measure HIF-induced transcription at 
normoxia and hypoxia of all cell lines in the presence 
and absence of the HIF-inhibitor (Figure 4A and 4B). 
By inhibiting VHL-dependent proteasomal degradation, 
DIP treatment accumulates HIFα and activates HIF 
transcriptional activity, reported via HRE-luciferase 
activity. Combined exposure to hypoxia further increased 
HIF transcriptional activity (Figure 4A), which might 
be due to loss of inhibitory hydroxylation of the HIFα 
N-terminal transactivating domain by factor inhibiting 
HIF (FIH-1) when oxygen is available. One μM 
of FM19G11 led to a several-fold and statistically 
significant decrease in HRE reporter activity compared 
to DIP alone in all tested cell lines at 72 h (Figure 4A 
and 4B). There was a tendency toward decreased HIF2α 
protein expression in the presence of the HIF inhibitor, 
(Supplementary Figure S3A).
We next tested the effect of FM19G11 on cell 
survival in the presence of antiestrogens. In antiestrogen-
resistant cells, under normoxic conditions (when HIF2α 
levels are high and HIF1α levels are low), FM19G11 
significantly increased sensitivity to tamoxifen in TAMR1 
cells and sensitivity to fulvestrant in FUR1 and FUR2 cells 
(Figure 4C). A slight increase in sensitivity to tamoxifen 
and fulvestrant was also observed for MCF-7 parental 
cells, albeit from very low to even lower viability levels 
(Figure 4C and Supplementary Figure S4). Increased 
concentrations of FM19G11 increased the effect of 
fulvestrant as shown in FUR2 (Figure 4D), the cell line 
with highest expression level of HIF2α. 
Overexpression of HIF2α increased cell viability 
in combination with antiestrogen treatment
To further examine the link between HIF2α 
expression and antiestrogen-resistance, an oxygen-stable 
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variant of HIF2α [26] was expressed in parental MCF-7 
cells by viral transduction. These cells (MCF-7 H2) 
expressed high levels of HIF2α protein at normoxia, which 
further increased with hypoxia (Figure 5A). In agreement, 
these cells also showed high HRE-luciferase activity, 
which further increased with hypoxia (Figure 5B). ARNT/
HIF1β was essentially uniformly expressed between 
subclones and conditions (Supplementary Figure S5). 
Next, we exposed HIF2α-overexpressing MCF-7 cells to 
antiestrogens and analyzed the percentage of surviving 
cells after six days at normoxia and hypoxia. The 
ectopically HIF2α-overexpressing MCF-7 cells were less 
sensitive to tamoxifen and fulvestrant than parental and 
control transduced MCF-7 cells (Figure 5C). At hypoxia, 
the treatment resistance inferred by HIF2α overexpression 
was even more pronounced, approaching resistance levels 
seen in TAMR1 and FUR2 cells (Figure 5C). We then 
co-exposed the virus-transduced cells to antiestrogens 
and FM19G11 HIF-inhibitor (2 μM) confirming that 
the HIF2α-induced resistance was counteracted by HIF-
inhibition (Figure 5D). In conclusion, overexpression of 
HIF2α increased the proportion of surviving cells in the 
presence of antiestrogens compared to control cells, and 
drug-sensitivity was rescued by HIF-inhibition.
Figure 2: Effect of hypoxia and antiestrogen treatment on HIF1α and HIF2α in MCF-7 and antiestrogen-resistant 
breast cancer cells. (A–C) MCF-7-derived cell lines with acquired resistance to tamoxifen (TAMR1) and fulvestrant (FUR1 and FUR2) 
were exposed to tamoxifen [0.5 μM] (T) or fulvestrant [0.5 μM] (F) under normoxic and hypoxic conditions for 72 h and analyzed for 
HIF1α and HIF2α protein expression by western blotting. SDHA was used as a loading control. The charts show quantification of the HIF2α 
levels normalized to SDHA in 3–4 independent experiments. Statistical analyses with one-tailed Student’s t-test, *p < 0.05, **p < 0.01, 
***p < 0.001. (D) Western blot analyses of ERα protein levels in whole cell lysates of TAMR1, FUR1, and FUR2 cells compared to MCF-7 
parental cells. Cells were harvested 72 h after addition of tamoxifen [0.5 μM] (T) or fulvestrant [0.5 μM] (F) to the growth medium under 
hypoxic (1%) or normoxic (21%) conditions. Actin was used as a loading control.
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Figure 3: Effect of hypoxia and antiestrogen on HIF2α mRNA expression in MCF-7 and antiestrogen resistant breast 
cancer cells. (A–C) Comparison of relative HIF2α mRNA levels in tamoxifen- (TAMR1) and fulvestrant- (FUR1 and FUR2) resistant 
cells exposed to tamoxifen [0.5 μM] (T) or fulvestrant [0.5 μM] (F) under normoxic and hypoxic conditions for 72 h. HIF2α mRNA 
levels were measured by qRT-PCR and normalized to the geometric mean of the expression of three reference genes: SDHA, UBC, and 
YWHAZ. A, B, and C in the chart denote three independent experiments. Statistical analyses with Student’s t-test, *p < 0.05, **p < 0.01, 
***p < 0.001. X acknowledges that the difference between groups was significant * in two out of three independent experiments. 
(D) Direct comparison of HIF2α mRNA levels in the different sub-cell lines at 21% and 1% oxygen. A, B, and C in the diagram denote 
three independent experiments. Statistical analyses with Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001. X denotes that the difference 
between the groups was significant * in two out of three independent experiments. HIF2α mRNA as measured in triplicate by qRT-PCR and 
normalized to the geometric mean of the expression of three reference genes: SDHA, UBC, and YWHAZ.
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HIF2α and EGFR protein levels are 
interdependent in antiestrogen-resistant cells
Since the fulvestrant-resistant cells were reported 
to express high levels of EGFR that contributes to their 
resistant phenotype [16], we investigated the effect 
of hypoxia on EGFR levels in antiestrogen-resistant 
and parental cells. EGFR expression was higher and 
increased in response to hypoxia in TAMR1, FUR1 and 
FUR2 cells (Figure 6A). Since HIF2α is reported to 
induce EGFR protein levels under hypoxic conditions in 
renal epithelial cells [14], we tested the effect of HIF2α 
downregulation by siRNA on EGFR protein levels in 
antiestrogen-resistant breast cancer cells. HIF2α silencing 
resulted in significantly lower levels of EGFR in both 
FUR1 and FUR2 cells at hypoxia (Figure 6B and 6C). 
Also in TAMR1 cells siHIF2α led to decreased EGFR 
expression, though initial levels were lower in these cells 
Figure 4: Effect of the HIF-inhibitor FM19G11 on HIF-transcriptional activity and response to antiestrogen treatment 
in MCF-7 and antiestrogen resistant breast cancer cells. (A–B) MCF-7, TAMR1, FUR1, and FUR2 cells transiently transfected 
with the HRE-luciferase reporter and a separate plasmid encoding Renilla luciferase were grown under normoxic or hypoxic conditions 
for 72 h and, over the final 24 h, all samples were exposed to dipyridyl [100 μM] with or without addition of the HIF-inhibitor FM19G11. 
(A) One representative experiment showing the absolute HRE-luciferase/Renilla luciferase activity ratio as the mean and SD of triplicates 
with and without addition of HIF inhibitor [1 μM]. (B) Statistical analyses of three independent experiments as described in panel A displaying 
the normalized fraction of HRE activity after addition of the HIF inhibitor [1 μM]. (C) Cell survival after exposure to tamoxifen (T) or 
fulvestrant (F) for six days shown as the percentage of non-drug exposed (C) cells with or without HIF inhibition with FM19G11 [1 μM]. 
Statistical analyses were with Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001. (D) Effect of increasing concentrations of FM19G11 
[0, 0.3, 1, and 3 μM] on cell survival in FUR2 cells that had the highest HIF2α levels exposed to fulvestrant.
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(data not shown). In agreement with these data, exposure 
of fulvestrant-resistant cells FUR2 to increasing levels 
of HIF-inhibitor (FM19G11) lead to increasingly lower 
EGFR levels (Supplementary Figure S3B). Furthermore, 
stable ectopic expression of HIF2α in parental MCF-7 
cells led to increased levels of EGFR (Figure 6D), 
confirming HIF2α-driven induction of EGFR. 
In addition to hypoxic accumulation, HIF1α and 
HIF2α can be induced in response to growth factor 
signaling; therefore, we tested the effect of EGFR 
downregulation on HIF2α protein expression. siEGFR 
decreased HIF2α protein levels under normoxia and 
hypoxia in antiestrogen resistant cells (Figure 6E, 
Supplementary Figure S6, and data not shown), suggesting 
that EGFR and HIF2α positively regulate each others 
expression. Furthermore, inhibiting the activity of EGFR 
by Gefitinib reduced HIF2α protein levels in the fulvestrant 
resistant cell line FUR2 (Supplementary Figure S6) 
especially under normoxic conditions.
DISCUSSION
The vast majority of women diagnosed with ERα-
positive breast cancer receive antiestrogen treatment. Anti-
hormonal therapy prevent cancer regrowth and metastasis, 
but in about 30% of patients receiving adjuvant tamoxifen, 
and in almost all patients with advanced breast cancer 
receiving tamoxifen, the cancer becomes resistant [2]. 
Figure 5: Effect of ectopic expression of stable HIF2α in MCF-7 cells on antiestrogen sensitivity. (A) Western blot analysis 
of HIF2α in the parental MCF-7 cells, MCF-7 cells transduced with empty vector (MCF-7C), and with the expression vector for stable 
HIF2α (MCF-7H2) and, for comparison, FUR2 cells. (B) HIF transcriptional activity in the control (MCF-7C) and HIF2A (MCF-7H2)-
transduced cells under normoxic and hypoxic conditions were analyzed by HRE-luciferase reporter activity. Data presented is the mean 
from three independent experiments in triplicate. (C) Cell viability of MCF-7 with (MCF-7H2) and without (MCF-7C) overexpression of 
stable HIF2α and tamoxifen or fulvestrant-resistant cells after 6-day exposure to tamoxifen (upper) or fulvestrant (lower) panel. (D) Cell 
viability of MCF-7 with (MCF-7H2) and without (MCF-7C) overexpression of stable HIF2α and tamoxifen or fulvestrant-resistant cells 
after 6-day co-exposure to HIF-inhibitor FM19G11 and tamoxifen (upper) or fulvestrant (lower) panel. Three independent experiments of 
triplicates were performed. Statistical analysis was with Student’s t-test.
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Currently, there is a lack of curative treatment for resistant 
breast cancer. Overcoming antiestrogen resistance is, 
therefore, a priority for breast cancer researchers, and 
a number of factors have been implicated in endocrine 
resistance including EGFR [16] and HIF-1 [12, 13, 27].
Tumor hypoxia is a well-established negative 
prognostic factor in cancer, including breast cancer 
[13, 28, 29]. Here, we show that hypoxia reduces responses 
to tamoxifen and fulvestrant in ERα-positive cells: MCF-7, 
CAMA-1, and T47D. The low oxygen conditions induced 
accumulation of both HIF1α and HIF2α, but after 24 h 
HIF1α levels were declining whereas HIF2α remained and 
effects on cell survival after antiestrogen exposure were 
seen after 6 days of hypoxia and drug exposure. HIF2α 
protein and mRNA expression were increased in a panel 
of antiestrogen-resistant cell lines, further establishing a 
link between hypoxia, HIF2α expression, and treatment 
resistance. Earlier reports showed that the cell line model 
of acquired antiestrogen-resistance used in this study, has 
clinical relevance since protein alterations reported in the 
resistant cell lines were found also in clinical samples from 
patients with antiestrogen-resistant breast cancers [30]. 
Our data demonstrate a direct link between HIF2α and 
antiestrogen resistance, since ectopic expression of HIF2α 
induced antiestrogen resistance in otherwise antiestrogen-
sensitive breast cancer cells. Furthermore, inhibition of 
Figure 6: Effect of downregulation of HIF2α on EGFR protein levels and downregulation of EGFR on HIF2α protein 
levels in MCF-7 and antiestrogen resistant cells. (A) Protein levels of EGFR in response to 24 h growth under hypoxic conditions 
in MCF-7, TAMR1, FUR1, and FUR2 cells. SDHA was used as a loading control. One representative experiment out of three independent 
experiments is shown. (B) The effect of downregulation of HIF2α on EGFR protein levels using two different siRNAs (H2A and H2B) was 
compared to the effect of two control siRNAs (C1 and C2). Samples were harvested 48 h after siRNA transfection and exposure to hypoxia 
or control conditions for 24 h. SDHA was used as a loading control. (C) Quantification of western blots of three independent repetitions 
of the experiment shown in B. (D) The EGFR protein levels in response to HIF2α overexpression by viral transduction (MCF-7 H2) 
compared to cells transduced with control vector (MCF-7 C). Loading control was SDHA. One representative experiment out of three 
independent experiments is shown. (E) HIF2α protein levels were analyzed in response to EGFR downregulation by siRNA knockdown. 
One representative experiment out of three independent experiments is shown. (F) Our present data suggest that HIF2α induces EGFR, 
which is a known contributor to resistance to antiestrogen therapy. Furthermore, we show that EGFR can induce HIF2α expression. Thus, 
EGFR and HIF2α exist with positive crosstalk to induce pro-malignant features including antiestrogen resistance. External factors such 
as tumor hypoxia and even therapy itself can fuel this interplay, as shown by the increased HIF2α expression in antiestrogen-treated cells.
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HIF-activity by FM19G11 under conditions where HIF2α 
is present, and HIF1α levels were not detected, restored 
antiestrogen sensitivity in the resistant cells, TAMR1, 
FUR1 and FUR2. Thus, we find HIF2α to be necessary and 
sufficient for the induction of antiestrogen resistance in the 
studied cells. Our findings highlight the potential feasibility 
of targeting HIF2α to overcome antiestrogen resistance. 
A similar situation is seen in clear cell renal carcinoma, 
where the negative regulator of HIF1α and HIF2α is 
frequently lost, and HIF2α is an oncoprotein and HIF1α 
acts as a tumor suppressor [31]. The transcriptional activity 
of HIF2α is less strictly regulated by oxygen conditions 
since factor inhibiting HIF1 (FIH1) has less affinity 
for HIF2α [32] allowing it to be active at physiological 
oxygen levels if accumulated as seen in the MCF-7 derived 
antiestrogen-resistant cell lines here. 
Our data suggest that one mechanism whereby 
HIF2α contributes to the antiestrogen resistance is by 
increasing the protein levels of EGFR (Figure 6E), which 
has been shown to play an important role for fulvestrant 
resistance in cell lines [16] and is inversely linked to 
antiestrogen-response in clinical samples [11]. EGFR 
knockdown and inhibition, in turn, demonstrated that 
EGF-signaling contributes to the high HIF2α levels in 
the resistant cells (Figure 6 and Supplementary Figure 6). 
Based on these data, we hypothesize that the collective 
activities of EGFR and HIF2α lead to therapeutic 
resistance and potentially other pro-malignant traits such 
as angiogenesis, proliferation and altered metabolism 
(Figure 6F). Our data suggest that this “vicious circle” is 
fueled by hypoxia and even antiestrogen-therapy itself, 
since tamoxifen, fulvestrant, and ERα downregulation 
increase HIF2α expression (Figure 2 and 3, and 
Supplementary Figure S2). Our present data are in line 
with the earlier publication by Franovic et al showing that 
HIF2α confers growth factor-independent proliferation 
to numerous cancers, including breast cancer, regardless 
of their tissue of origin or mutational status and that the 
proliferative effect was exerted via receptor tyrosine 
kinases, including EGFR [33].
The general view is that HIF1α and HIF2α are 
mainly regulated post-translationally by oxygen-dependent 
proteasomal degradation [34, 35]. However, growth factor 
signaling has been shown to regulate HIF1α at both the 
transcriptional and translational level [36–41], and HIF2α 
transcription in hypoxic neuroblastoma cells is regulated 
by IGF-2 [23, 42]. Here, we show that EGFR knockdown 
downregulates the high HIF2α levels in antiestrogen-
resistant cells (Figure 6E and 6F). 
Tamoxifen-resistant cell growth has previously 
been shown to depend on ERα [30] and recently to be 
due to crosstalk with the Aurora kinase A [43], which 
is a determinant of tamoxifen sensitivity through 
phosphorylation of ERα [44]. Despite that we find ERα 
protein expression being downregulated by hypoxia, 
a phenomenon that can be linked to HIF1α [45], ERα 
signaling persisted under hypoxic conditions (Figure 1C). 
HIF1α has been reported to promote ligand-independent 
ERα signaling, presumably, by direct binding of HIF1α 
to ERα [46]. Given the high homology between HIF1α 
and HIF2α, HIF2α may also be able to propagate ERα 
signaling; this requires experimental validation. 
As mentioned above, tamoxifen-resistant cells, 
including TAMR1, depend on ERα-activity also in the 
presence of tamoxifen [30, 43]. The situation is quite 
different in fulvestrant treatment and fulvestrant-resistant 
cells where ERα is lost because of the destabilizing 
effect of fulvestrant-binding and the resistant cells take 
advantage of ERα independent mechanisms including 
activation of HER/EGFR pathways [16]. A similar 
setting to fulvestrant treatment is the exposure to siERα 
(Supplementary Figure 2) where we see increased 
HIF2α levels. The fact that HIF2α infers resistance to 
both tamoxifen and fulvestrant and that HIF-inhibition/
downregulation increases sensitivity to both tamoxifen 
and fulvestrant indicates that HIF2α confers increased 
antiestrogen resistance in a general manner.
The frequent presence of tumor hypoxia, HIF1α, and 
HIF2α in solid tumors, including breast cancer, suggests 
that these tumor areas may possess inherent antiestrogen 
resistance that can withstand therapy and contribute 
to treatment failure. It now appears that antiestrogen 
treatment itself might exacerbate the resistance 
phenotype. Our finding that HIF inhibition by FM19G11 
restores antiestrogen sensitivity indicates that targeting 
HIF activity may be a feasible strategy to counteract 
antiestrogen resistance in clinical practice. However, this 
requires further investigation in the clinical setting. 
MATERIALS AND METHODS
Cells and cell culture
The ERα-positive human breast cancer cells 
MCF-7, CAMA-1, and T47D were obtained from the 
American Type Culture Collection (ATCC, USA). The 
MCF-7/S0.5 subline (MCF-7, parental cells) and the 
antiestrogen resistant strains that were derived from this 
cell line, MCF-7/TAMR-1 (TAMR1), MCF-7/182R-6 
(FUR1) and MCF-7/164R-7 (FUR2) were obtained from 
Anne Lykkesfeldt, Danish Cancer Society Research 
Center. The MCF-7 sub-line was established by stepwise 
reduction of the serum concentration from 5% to 0.5% 
[17]. The tamoxifen-resistant TAMR-1 cell line and the 
fulvestrant-resistant cell lines FUR1 and FUR2 were 
established by long term selection with 1 μM tamoxifen, 
0.1 μM ICI 182,780 (fulvestrant) and 0.1 μM ICI 164,384, 
respectively, as previously described [18, 19]. Due to the 
long periods of culture, MCF-7 cell line authenticity 
was tested and positively confirmed (DSMZ, Germany). 
All cells were grown in standard DMEM/F12 medium 
(Thermo Fisher Scientific, MA) with FCS (MCF-7, 
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TAMR1, FUR1, and FUR2: 1%; T47D and CAMA-1: 
10%, Biosera, MO), penicillin and streptomycin 
(100 units/ml, Hyclone, GE Healthcare, UT) and insulin 
(100 units/ml, Actrapid, Novo Nordisk, Denmark). The 
cells were routinely cultured at 37°C, 5% CO
2
, and 
air oxygen levels, kept at low passage numbers, and 
checked for Mycoplasma on a monthly basis (results 
were consistently negative). Antiestrogen-resistant cells 
were maintained in their respective antiestrogen until 
1–2 weeks prior to experimental use. Growth medium 
with additives was changed every third day. Hypoxic cell 
culture experiments were performed in a Don Whitley 
Hypoxystation (Don Whitley Scientific, Shipley, UK) 
under identical culture conditions except for oxygen. Cells 
were treated with tamoxifen (4-hydroxytamoxifen; Sigma 
Aldrich, MO; 0.5 μM) or fulvestrant (ICI 182.780; Tocris 
Bioscience, UK; 0.5 μM) as indicated.
Immunoblotting
Whole cell lysates (40–80 µg protein in RIPA buffer 
with Complete, Roche, Switzerland) were electrophoretically 
separated (7.5% Mini TGX gel, BioRad Laboratories CA). 
Protein detection was performed using anti-HIF1α (Becton 
Dickinson, NJ), anti-HIF1β (Ab126985) anti-HIF2α 
(Ab199, Abcam, UK), anti-EGFR (DAK-H1-WT, Dako, 
Denmark), ERα (Cell Signaling Technologies, MA), actin 
(MP Biomedicals, CA) and SDHA (Ab14715, Abcam). 
RNA isolation, cDNA synthesis, and qRT-PCR
cDNA was generated from purified RNA 
(QIAshredder, RNeasy, Qiagen, Netherlands, Applied 
Biosystems). Genomic DNA was removed by RNase-
free DNase (Promega, WI). qRT-PCR was performed 
(7300 RT-PCR, Applied Biosystems) with SYBR Green 
(Applied Biosystems) using forward and reverse primers 
for: HIF1α (f-5ʹTTCCAGTTACGTTCCTTCGATCA3ʹ, 
r-5ʹTTTGAGGACT-TGCGCTTTCA3ʹ), HIF2α (f-5ʹGC 
TCTCCACGGCCTGATA3ʹ, r-5ʹTTGTCACAC-CTATGG 
CATATCACC3ʹ) and EGFR (f-5ʹCTAATTTGGTGGCTG 
CCTTTCT3ʹ, r-5ʹCCCGAGTATCTCAACACTGTCC3ʹ). 
Gene expression was normalized using the geometric 
mean of three reference genes: SDHA (f- 5ʹTGGGAACA 
AGAGGGCATC-TG3ʹ, r 5ʹCCACCACTGCATCAAATT 
CATG3ʹ), UBC (f-5ʹATTTGGGTCGCGGTT-CTTG3ʹ, 
r 5ʹTGCCTTGACATTCTCGATGGT3ʹ), and YWHAZ 
(f-5ʹACTTTTGGTACA-TTGTGTGGCTTCAA3ʹ, r- 5ʹCC 
GCCAGGACAAACCAGTAT3ʹ).
Cell counting
Cells were exposed to the specified conditions 
six days prior to detachment, trypan blue staining, and 
counting in an automated cell counter according to the 
manufacturer’s protocol (Countess, Life Technologies).
WST-1 assay
Cells were treated with the specified conditions in 
96-well plates for up to nine days. Relative viable cell 
numbers were measured by WST-1 (Roche) at normoxia 
after change to normoxic growth medium to minimize 
the risk that hypoxia would interfere with the detection 
of metabolically active cells. Optical densities were 
measured at 450 and 630 nm (Synergy 2, BioTek, VT). 
Luciferase assays
Cells were transfected with HRE-luc or 
ERE-luc reporter constructs (HRE, Addgene, MA, 
#26731 deposited by N Chandel; ERE; pGL2 luciferase 
reporter plasmid with ERα-responsive element) and 
pRL-SV40 (internal control). For ERE-luc analyses, cells 
were kept in standard growth medium supplemented with 
10 nM estrogen, 1 µM tamoxifen, or both and cultured 
72 h in 21% or 1% oxygen. Cell lysates were analyzed 
using Dual-Luciferase Reporter Assay (Promega) and 
normalized to internal controls.
HIF inhibitor
FM19G11 (Calbiochem, Merck Millipore, MA) 
[25, 47] was diluted in DMSO and used at final 
concentrations of 0.5–3.0 μM. The corresponding amount 
of DMSO was added to controls.
Ectopic expression of HIF2A and gene silencing
Parental MCF-7 cells was transduced with the 
retroviral vector encoding a stable version of HIF2α 
HA-HIF2α P531A-pBabe-puro (Addgene; Dr. W.G. 
Kaelin) [26] or empty pBabe-puro. Transduced cells 
were selected by puromycin. HIF2α silencing was 
performed using two custom made siRNAs targeting 
different HIF2α mRNA regions and two control 
siRNAs (Life Technologies). EGFR silencing was 
performed using validated silencer siEGFR (s563 and 
s564) and controls (Life Technologies). ERα silencing 
was performed using pre-designed siRNAs (s4823 and 
s4825) and controls (Life Technologies).
Statistical analyses
Statistical analyses were conducted in GraphPad 
Prism 6.0 (GraphPad Software, CA). Student’s t-test was 
performed and results are shown as mean +/– 1SD with 
p-values: *p < 0.05, **p < 0.01, ***p < 0.001. 
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